How could breast cancer molecular features contribute to locoregional treatment decision making?

Tsoutsou, Pelagia G.; Vozenin, Marie-Catherine; Durham, André-Dante; Bourhis, Jean

doi:10.1016/j.critrevonc.2016.12.006

Cited by 44 publications

(38 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has been reported that the Her2-enriched and TN subtypes of breast cancer are the most susceptible to locoregional failure [44,45]. Further, patients with the TN subtype had a signi cantly higher risk of RR than those with the other subtypes, while no signi cant difference was found in the risk of LR [46][47][48].…”

Section: Discussionmentioning

confidence: 97%

Locoregional recurrence patterns in women with breast cancer who have not undergone post-mastectomy radiotherapy

Zhao

Tang

Wang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background : To analyze the patterns of locoregional recurrence in breast cancer patients after mastectomy. Methods : The retrospective study included 7073 women with breast cancer without post-mastectomy radiotherapy: 4604 (65.1%) had pT1-2N0 disease (low risk); 2042 (28.9%), pT1-2N1 (intermediate risk); and 427 (6.0%), pT3-4 and/or pN2-3, or pT1-2N1 after neoadjuvant chemotherapy (high risk). The distribution of cumulative locoregional recurrence was analyzed. The local recurrence and regional recurrence rates were estimated by the Kaplan-Meier method, and differences were compared with the log-rank test. Multivariate analysis was performed using Cox logistic regression analysis. Results: In the median follow-up of 63.0 months, 469 patients had locoregional recurrence: chest wall recurrence in 238 cases (50.7%), supraclavicular/infraclavicular nodes in 236 (50.3%) cases, axilla in 92 (19.6%), and internal mammary nodes in 50 (10.7%) cases. The 5-year local recurrence and regional recurrence rates were 2.5% and 4.4%, respectively. Subgroup analysis of the three risk groups and five molecular subtypes (luminal A, luminal B-Her2 negative, luminal B-Her2 positive, Her2-enriched, and triple negative) also showed that the chest wall and supraclavicular/infraclavicular nodes were the most common recurrence sites. Age, tumor location, T stage, N stage, and hormone receptor status were independent prognostic factors for both local recurrence and regional recurrence (p < 0.05). Conclusions: The chest wall and supraclavicular/infraclavicular nodes are common sites of locoregional recurrence in breast cancer, irrespective of disease stage or molecular subtype, and the prognostic factors for local recurrence and regional recurrence are similar. Therefore, chest wall and supraclavicular/infraclavicular nodes irradiation should always be considered in post-mastectomy radiotherapy.

show abstract

Section: Discussionmentioning

confidence: 97%

Locoregional recurrence patterns in women with breast cancer who have not undergone post-mastectomy radiotherapy

Zhao

Tang

Wang

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…These discoveries demonstrate the potential for genomics to transform breast cancer treatment (Hamdan et al, 2019). For instance, genomics helped identify patients for clinical trials (Curtis et al, 2012) or high risk individuals through mutation screening in breast cancer susceptibility (BRCA) 1-2 genes (Evans et al, 2008) and contributed to therapeutic decision making (Tsoutsou et al, 2017;Bergom et al, 2019). As an invaluable resource for researchers, the Catalogue of Somatic Mutations in Cancer (COSMIC) has compiled genomic data from breast cancer patient samples and correlated them to cellular functions and drug resistance (Forbes et al, 2017).…”

Section: Genomicsmentioning

confidence: 99%

‘Omics Approaches to Explore the Breast Cancer Landscape

Parsons

Francavilla

2020

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Breast cancer incidence is increasing worldwide with more than 600,000 deaths reported in 2018 alone. In current practice treatment options for breast cancer patients consists of surgery, chemotherapy, radiotherapy or targeting of classical markers of breast cancer subtype: estrogen receptor (ER) and HER2. However, these treatments fail to prevent recurrence and metastasis. Improved understanding of breast cancer and metastasis biology will help uncover novel biomarkers and therapeutic opportunities to improve patient stratification and treatment. We will first provide an overview of current methods and models used to study breast cancer biology, focusing on 2D and 3D cell culture, including organoids, and on in vivo models such as the MMTV mouse model and patient-derived xenografts (PDX). Next, genomic, transcriptomic, and proteomic approaches and their integration will be considered in the context of breast cancer susceptibility, breast cancer drivers, and therapeutic response and resistance to treatment. Finally, we will discuss how 'Omics datasets in combination with traditional breast cancer models are useful for generating insights into breast cancer biology, for suggesting individual treatments in precision oncology, and for creating data repositories to undergo further meta-analysis. System biology has the potential to catalyze the next great leap forward in treatment options for breast cancer patients.

show abstract

“…This type of BC does not benefit from hormonal therapy or anti-human epidermal growth factor receptor 2 medications. 44 Recently, it has emerged that patients with triple-negative BC, specifically estrogen negative, have lower cathelicidin antimicrobial peptide (CAMP), an important cytotoxic and proapoptotic peptide. Patients with tumor estrogen-negative cells produce less CAMP than the others, but it appears that if the cells are stimulated with calcitriol, CAMP levels rise, leading to potential benefits for treatment.…”

Section: Vitamin D and Bcmentioning

confidence: 99%

Immune Modulation by Vitamin D: Special Emphasis on Its Role in Prevention and Treatment of Cancer

Pandolfi

Franza

Mandolini

et al. 2017

Clinical Therapeutics

View full text Add to dashboard Cite

show abstract

How could breast cancer molecular features contribute to locoregional treatment decision making?

Cited by 44 publications

References 71 publications

Locoregional recurrence patterns in women with breast cancer who have not undergone post-mastectomy radiotherapy

Locoregional recurrence patterns in women with breast cancer who have not undergone post-mastectomy radiotherapy

‘Omics Approaches to Explore the Breast Cancer Landscape

Immune Modulation by Vitamin D: Special Emphasis on Its Role in Prevention and Treatment of Cancer

Contact Info

Product

Resources

About